165 related articles for article (PubMed ID: 8808490)
1. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.
Kang SS; Wong PW
Atherosclerosis; 1996 Jan; 119(2):135-8. PubMed ID: 8808490
[TBL] [Abstract][Full Text] [Related]
2. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia.
Yoo JH; Choi GD; Kang SS
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1921-5. PubMed ID: 10938012
[TBL] [Abstract][Full Text] [Related]
3. Causes and consequences of hyperhomocyst(e)inemia.
Pietrzik K; Brönstrup A
Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects.
Legnani C; Palareti G; Grauso F; Sassi S; Grossi G; Piazzi S; Bernardi F; Marchetti G; Ferraresi P; Coccheri S
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2924-9. PubMed ID: 9409277
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Quehenberger F; Semmelrock J; Haas A
Ophthalmology; 2002 Jun; 109(6):1105-9. PubMed ID: 12045051
[TBL] [Abstract][Full Text] [Related]
8. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis.
Rees MM; Rodgers GM
Thromb Res; 1993 Sep; 71(5):337-59. PubMed ID: 8236162
[No Abstract] [Full Text] [Related]
9. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.
Manns BJ; Burgess ED; Hyndman ME; Parsons HG; Schaefer JP; Scott-Douglas NW
Am J Kidney Dis; 1999 Oct; 34(4):669-77. PubMed ID: 10516348
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives.
Beaumont V; Malinow MR; Sexton G; Wilson D; Lemort N; Upson B; Beaumont JL
Atherosclerosis; 1992 Jun; 94(2-3):147-52. PubMed ID: 1632868
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
[TBL] [Abstract][Full Text] [Related]
13. The many flavors of hyperhomocyst(e)inemia: insights from transgenic and inhibitor-based mouse models of disrupted one-carbon metabolism.
Elmore CL; Matthews RG
Antioxid Redox Signal; 2007 Nov; 9(11):1911-21. PubMed ID: 17696766
[TBL] [Abstract][Full Text] [Related]
14. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.
Watanabe M; Osada J; Aratani Y; Kluckman K; Reddick R; Malinow MR; Maeda N
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1585-9. PubMed ID: 7878023
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
Falcon CR; Cattaneo M; Panzeri D; Martinelli I; Mannucci PM
Arterioscler Thromb; 1994 Jul; 14(7):1080-3. PubMed ID: 8018663
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
[TBL] [Abstract][Full Text] [Related]
18. Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocyst(e)ine concentrations.
Malinow MR; Duell PB; Williams MA; Kruger WD; Evans AA; Anderson PH; Block PC; Hess DL; Upson BM; Graf EE; Irvin-Jones A; Wang L
Lipids; 2001; 36 Suppl():S27-32. PubMed ID: 11837988
[TBL] [Abstract][Full Text] [Related]
19. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background.
Moghadasian MH; McManus BM; Frohlich JJ
Arch Intern Med; 1997 Nov; 157(20):2299-308. PubMed ID: 9361570
[TBL] [Abstract][Full Text] [Related]
20. Mild hyperhomocyst(e)inemia: a possible risk factor for cervical artery dissection.
Gallai V; Caso V; Paciaroni M; Cardaioli G; Arning E; Bottiglieri T; Parnetti L
Stroke; 2001 Mar; 32(3):714-8. PubMed ID: 11239192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
